Long-term follow-up of patients receiving hematopoietic stem cell transplantation (HSCT) for severe scleroderma has confirmed a durable survival benefit compared to conventional treatment with cyclophosphamide. The findings, presented at the 2018 ACR/ARHP Annual Meeting in Chicago, extend the findings from the SCOT trial published earlier this year. In the SCOT trial, 75 patients with severe ...
Already a member?
Enter your email to keep reading.